Louise Møller Jørgensen

Louise Møller Jørgensen


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2014 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Open access
AEAnders Ettrup
Anders Ettrup
SCSophie da Cunha-Bang
Sophie da Cunha-Bang
BMBrenda McMahon
Brenda McMahon
SLSzabolcs Lehel
Szabolcs Lehel
ADAgnete Dyssegaard
Agnete Dyssegaard
GKGitte Moos Knudsen
Gitte Moos Knudsen
[ 11 C]Cimbi-36 was recently developed as a selective serotonin 2A (5-HT2A) receptor agonist radioligand for positron emission tomography (PET) brain imaging. Such an agonist PET radioligand may provide a novel, and more functional, measure of the serotonergic system and agonist binding is more likely than antagonist binding to reflect 5-HT levels in vivo. Here, we show data from a first-in-human clinical trial with [ 11 C]Cimbi-36. In 29 healthy volunteers, we found high brain uptake and distribution according to 5-HT2A receptors with [ 11 C]Cimbi-36 PET. The two-tissue compartment model using arterial input measurements provided the most optimal quantification of cerebral [ 11 C]Cimbi-36 binding. Reference tissue modeling was feasible as it induced a negative but predictable bias in [ 11 C]Cimbi-36 PET outcome measures. In five subjects, pretreatment with the 5-HT2A receptor antagonist ketanserin before a second PET scan significantly decreased [ 11 C]Cimbi-36 binding in all cortical regions with no effects in cerebellum. These results confirm that [ 11 C]Cimbi-36 binding is selective for 5-HT2A receptors in the cerebral cortex and that cerebellum is an appropriate reference tissue for quantification of 5-HT2A receptors in the human brain. Thus, we here describe [ 11 C]Cimbi-36 as the first agonist PET radioligand to successfully image and quantify 5-HT2A receptors in the human brain.

1 April 2016 in NeuroImage
Verified
Journal Article
Closed access
AEAnders Ettrup
Anders Ettrup
CSClaus Svarer
Claus Svarer
BMBrenda McMahon
Brenda McMahon
SCSofi da Cunha-Bang
Sofi da Cunha-Bang
SLSzabolcs Lehel
Szabolcs Lehel
GKGitte Moos Knudsen
Gitte Moos Knudsen

20 July 2016 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Closed access
LJLouise Møller Jørgensen
Louise Møller Jørgensen
PWPia Weikop
Pia Weikop
JVJonas Villadsen
Jonas Villadsen
TVTanel Visnapuu
Tanel Visnapuu
AEAnders Ettrup
Anders Ettrup
GKGitte Moos Knudsen
Gitte Moos Knudsen
Positron emission tomography (PET) can, when used with appropriate radioligands, non-invasively generate temporal and spatial information about acute changes in brain neurotransmitter systems. We for the first time evaluate the novel 5-HT2Areceptor agonist PET radioligand, [11C]Cimbi-36, for its sensitivity to detect changes in endogenous cerebral 5-HT levels, as induced by different pharmacological challenges. To enable a direct translation of PET imaging data to changes in brain 5-HT levels, we calibrated the [11C]Cimbi-36 PET signal in the pig brain by simultaneous measurements of extracellular 5-HT levels with microdialysis and [11C]Cimbi-36 PET after various acute interventions (saline, citalopram, citalopram + pindolol, fenfluramine). In a subset of pigs, para-chlorophenylalanine pretreatment was given to deplete cerebral 5-HT. The interventions increased the cerebral extracellular 5-HT levels to 2–11 times baseline, with fenfluramine being the most potent pharmacological enhancer of 5-HT release, and induced a varying degree of decline in [11C]Cimbi-36 binding in the brain, consistent with the occupancy competition model. The observed correlation between changes in the extracellular 5-HT level in the pig brain and the 5-HT2Areceptor occupancy indicates that [11C]Cimbi-36 binding is sensitive to changes in endogenous 5-HT levels, although only detectable with PET when the 5-HT release is sufficiently high.

1 January 2018 in Journal of Neuroscience Methods
Verified
Journal Article
Closed access
JVJonas Villadsen
Jonas Villadsen
HHHanne Hansen
Hanne Hansen
LJLouise Møller Jørgensen
Louise Møller Jørgensen
SKSune H. Keller
Sune H. Keller
FAFlemming Littrup Andersen
Flemming Littrup Andersen
CSClaus Svarer
Claus Svarer

1 October 2005 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
LJLouise Møller Jørgensen
Louise Møller Jørgensen
JNJørgen Erik Nielsen
Jørgen Erik Nielsen
MRM. Ravnborg
M. Ravnborg

11 April 2019 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
SCSofi da Cunha-Bang
Sofi da Cunha-Bang
AEAnders Ettrup
Anders Ettrup
BMBrenda Mc Mahon
Brenda Mc Mahon
ASAnine Persson Skibsted
Anine Persson Skibsted
MSMartin Schain
Martin Schain
GKGitte Moos Knudsen
Gitte Moos Knudsen
Developing positron emission tomography (PET) radioligands for the detection of endogenous serotonin release will enable the investigation of serotonergic deficits in many neuropsychiatric disorders. The present study investigates how acute challenges that aim to increase or decrease cerebral serotonin levels affect binding of the serotonin 2A receptor (5-HT2AR) agonist radioligand [11C]Cimbi-36. In a randomized, double-blind, placebo-controlled, three-arm design, 23 healthy volunteers were PET scanned twice with [11C]Cimbi-36: at baseline and following double-blind assignment to one of three interventions (1) infusion of the selective serotonin reuptake inhibitor (SSRI) citalopram preceded by oral dosing of the 5-HT1AR antagonist pindolol, (n = 8) (2) acute tryptophan depletion (ATD) (n = 7) and (3) placebo (n = 8). Two-sample t-tests revealed no significant group differences in percent change of neocortical [11C]Cimbi-36 binding from baseline to intervention between placebo and citalopram/pindolol (p = 0.4) or between placebo and ATD (p = 0.5). Notably, there was a significantly larger within-group variation in 5-HT2AR binding after intervention with citalopram/pindolol, as compared with placebo (p = 0.007). These findings suggest that neither ATD nor a combination of citalopram and pindolol elicit acute unidirectional changes in serotonin levels sufficient to be detected with [11C]Cimbi-36 PET in neocortex. We suggest that the large interindividual variation in 5-HT2AR binding after citalopram/pindolol reflects that after an acute SSRI intervention, individuals respond substantially different in terms of their brain serotonin levels. Our observation has a potential impact for the understanding of patient responses to SSRI.